ACT Capital Management LLC Invests $718,000 in Teva Pharmaceutical Industries Ltd. $TEVA

ACT Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 23,000 shares of the company’s stock, valued at approximately $718,000.

Several other large investors also recently modified their holdings of TEVA. AQR Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth lifted its holdings in shares of Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after purchasing an additional 1,739 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $255,000. Flow Traders U.S. LLC bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $238,000. Finally, Cerity Partners LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 2.9% in the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after purchasing an additional 1,291 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $32.59 on Thursday. The company has a market cap of $37.47 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 3.36 and a beta of 0.84. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a 50-day moving average price of $33.46 and a 200-day moving average price of $32.17. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of recent research reports. UBS Group increased their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Finally, JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Buying and Selling

In related news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the sale, the executive vice president owned 55,755 shares in the company, valued at $1,973,727. The trade was a 34.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the completion of the sale, the executive vice president owned 63,647 shares of the company’s stock, valued at $2,247,375.57. The trade was a 25.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 465,931 shares of company stock worth $16,332,989 over the last ninety days. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.